发帖
雷达卡
The Diagnosis
EU Large Cap Pharma - The 2009 Outlook
Pharmaceuticals
Alexandra HauberAC
(44-20) 7742-6655 / (1-312) 325-3694
alexandra.m.hauber@jpmorgan.com
Richard Vosser
(44-20) 7742-6652
richard.vosser@jpmorgan.com
David P Evans
(44-20) 7742-6659
david.p.evans@jpmorgan.com
James D Gordon
(44-20) 7742-6654
james.d.gordon@jpmorgan.com
J.P. Morgan Securities Ltd.
For Specialist Sales advice, please
contact:
Marjan Daeipour
(44 20) 7325-3281
marjan.daeipour@jpmorgan.com
See page 69 for analyst certification and important disclosures, including non-US analyst disclosures.
J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may
have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their
investment decision. Customers of J.P. Morgan in the United States can receive independent, third-party research on the company or companies
covered in this report, at no cost to them, where such research is available. Customers can access this independent research at
www.morganmarkets.com or can call 1-800-477-0406 toll free to request a copy of this research.
Please also see our notes
published earlier today on Glaxo
SmithKline and Sanofi-Aventis
• Large-cap rankings revisited: We rate four mid-cap stocks as Overweight
(Novo Nordisk, Merck KGaA, Shire, Ipsen) due to our perception of greater
potential for re-rating from currently low valuations. However, Overweightrated
mid-cap stocks represent only 9% of our investable pharma universe.
Thus, the relative weighting of the pharma large caps remains important.
Rankings are based on a 12-month view.
• Valuation: limited downside with opportunities. All five pharma large
caps trade at or below our Embedded Value (EmV) estimates. In our view,
this suggests that after 9 years of multiple compression, the 2011-2013
patent cliff is now largely priced in. We believe a catalyst-rich 2009
should offer opportunities for significant re-ratings, particularly for
SASY and AZN.
• Roche (Overweight) remains our No. 1 pick as we believe that the
company’s under-appreciated long-term upside may return to focus once
uncertainty on the Genentech transaction is out of the way.
• Sanofi-Aventis: upgraded to Neutral and moved to No. 2 with a
multiples-based Dec ‘09 price target of
京公网安备 11010802022788号
